Targeted Cancer Immune Therapy

  • Joseph Lustgarten
  • Yan Cui
  • Shulin Li

Table of contents

  1. Front Matter
    Pages i-xi
  2. Cytokine Immune Therapy

    1. Front Matter
      Pages 1-1
    2. Chintana Chirathaworn, Yong Poovorawan
      Pages 19-41
    3. Ian D. Davis, Kresten Skak, Naomi Hunder, Mark J. Smyth, Pallavur V. Sivakumar
      Pages 43-59
    4. Sita Aggarwal, William Hansel, Rajasree Solipuram
      Pages 61-74
    5. Jeffry Cutrera, Shulin Li
      Pages 97-113
  3. Cell-based Immune Therapy

    1. Front Matter
      Pages 116-116
    2. Jian Qiao, Haidong Dong
      Pages 117-131
    3. Archana Monie, Chien-Fu Hung, T.-C. Wu
      Pages 133-157
    4. Eduardo Davila
      Pages 173-189
    5. Wesley Burnside, Yan Cui
      Pages 191-206
    6. Faisal Razzaqi, Wesley M. Burnside, Lolie Yu, Yan Cui
      Pages 207-223
  4. Targeted Immune Therapy

    1. Front Matter
      Pages 226-226
    2. Danice E. C. Wilkins, William J. Murphy
      Pages 227-239
    3. Jessica B. Katz, Alexander J. Muller, Richard Metz, George C. Prendergast
      Pages 257-283
    4. Dinorah Friedmann-Morvinski, Zelig Eshhar
      Pages 285-299
    5. Joseph Lustgarten, Dominique Hoelzinger, Maria Adelaida Duque, Shannon Smith, Noweeda Mirza
      Pages 301-318
  5. Back Matter
    Pages 337-343

About this book


Cancer has surpassed heart disease as the number one killer in the world, and standard cancer therapy such as radiation, chemotherapy, and surgery may have reached its plateau in further improving the outcome of treated patients. Biological therapies combined with other treatment approaches may be the next X-factor to greatly extend survival time and improve patients’ quality of life. One of the most developed fields in biological therapy is immune therapy, which has stemmed into many branches due to its significance and the tremendous effort by a large population of scientists. Tumor-targeted antibody therapy has been successfully used for treating some types of tumors, and the first tumor vaccine against ovarian cancer has been developed for clinical application.

Targeted Cancer Immune Therapy provides comprehensive coverage of novel immune therapeutic approaches, including cytokine therapy, engineered cell therapy, and the application of tumor-targeted antibodies for generating tumor-specific cell therapy, TLR ligand therapy, and cytokine therapy. In the section "Cytokine Immune Therapy," the authors review relatively new cytokine family members, such as the IL12 family, IL18, IL21, IL24, IL28, and IL29, in regard to the anti-tumor function and application in treating tumors. The strategy for targeting and retaining cytokines in the tumor microenvironment is also reviewed. The section "Cell-based Immune Therapy" focuses on reviewing "state of the art" approaches for engineering potent immune regulatory or effector cells, such as dendritic cells, T cells, and stem cells, for tumor targeting and initiation of tumor specific immune response. In the section "Targeted Immune Therapy," the authors rearticulate antibody therapy for boosting immune response, which includes immunocytokines, "T-body," and tumor targeted CpG ODN. Some or all of these innovative approaches may ultimately become effective future immune therapies for treating malignancy.


TNF cancer cancer therapy cell cell therapy clinical trial cytokine cytokines immunotherapy tumor vaccine

Editors and affiliations

  • Joseph Lustgarten
    • 1
  • Yan Cui
    • 2
  • Shulin Li
    • 3
  1. 1.Sidney Kimmel Cancer CenterSan DiegoU.S.A.
  2. 2.Health Sciences CenterLouisiana State UniversityNew OrleansU.S.A.
  3. 3.School of Veterinary MedicineLouisiana State UniversityBaton RougeU.S.A.

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods